Leading Pharmaceutical Innovation: Trends and Drivers for Growth in the Pharmaceutical Industry
Autor Oliver Gassmann, Gerrit Reepmeyer, Maximilian von Zedtwitzen Limba Engleză Paperback – 6 noi 2010
| Toate formatele și edițiile | Preț | Express |
|---|---|---|
| Paperback (1) | 388.66 lei 38-45 zile | |
| Springer – 6 noi 2010 | 388.66 lei 38-45 zile | |
| Hardback (1) | 379.96 lei 6-8 săpt. | |
| Springer Berlin, Heidelberg – 3 mar 2008 | 379.96 lei 6-8 săpt. |
Preț: 388.66 lei
Preț vechi: 479.82 lei
-19% Nou
Puncte Express: 583
Preț estimativ în valută:
74.37€ • 78.42$ • 61.92£
74.37€ • 78.42$ • 61.92£
Carte tipărită la comandă
Livrare economică 06-13 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783642096389
ISBN-10: 3642096387
Pagini: 204
Dimensiuni: 155 x 235 x 11 mm
Greutate: 0.29 kg
Ediția:Softcover reprint of hardcover 2nd ed. 2008
Editura: Springer
Colecția Springer
Locul publicării:Berlin, Heidelberg, Germany
ISBN-10: 3642096387
Pagini: 204
Dimensiuni: 155 x 235 x 11 mm
Greutate: 0.29 kg
Ediția:Softcover reprint of hardcover 2nd ed. 2008
Editura: Springer
Colecția Springer
Locul publicării:Berlin, Heidelberg, Germany
V-ar putea interesa
-
Competing Against Luck: The Story of Innovation and Customer ChoiceClayton M. ChristensenPreț: 120.75 lei -
-18%Preț: 197.97 lei241.43 lei -
Product Platform and Product Family Design: Methods and ApplicationsTimothy W. Simpson-18%Preț: 1637.16 lei1996.53 lei -
Preț: 127.43 lei -
Preț: 246.78 lei -
More Than a Showroom: Strategies for Winning Back Online ShoppersDaniel G. BachrachPreț: 205.54 lei -
Preț: 96.41 lei -
-12%Preț: 315.84 lei359.27 lei -
Product LeadershipRichard BanfieldPreț: 213.06 lei -
Make No Mistake!: An Outcome-Based Approach to Mistake-ProofingC. Martin Hinckley-25%Preț: 502.62 lei670.61 lei -
Scrum in easy stepsDavid MorrisPreț: 76.98 lei -
-15%Preț: 630.83 lei742.15 lei -
-14%Preț: 565.02 lei657.00 lei
Public țintă
Professional/practitionerDescriere
Pharmaceutical
giants
have
doubled
their
investments
in
drug
development
in
the
past
decade
only
to
see
new
drug
approvals
remain
constant.
This
book
investigates
and
highlights
a
set
of
proactive
strategies
aimed
at
generating
sustainable
competitive
advantage
based
on
value-generating
business
practices.
We
focus
on
three
sources
of
pharmaceutical
innovation:
new
management
methods
in
the
drug
development
pipeline,
new
technologies
as
enablers
for
cutting-edge
R&D,
and
new
forms
of
cooperation
and
internationalization,
such
as
open
innovation
in
the
early
phases
of
R&D.
Our
findings
are
illustrated
by
cases
from
Europe,
the
US,
and
Asia.
Cuprins
Innovation:
Key
to
Success
in
the
Pharmaceutical
Industry.-
The
Industry
Challenge:
Do
You
Really
Want
to
Be
in
This
Business?.-
The
Science
and
Technology
Challenge:
How
to
Find
New
Drugs.-
The
Pipeline
Management
Challenge:
How
to
Organize
Innovation.-
The
Internationalization
Challenge:
Where
to
Get
Access
to
Innovation.-
Management
Answers
to
Pharmaceutical
R&D
Challenges.-
Future
Directions
and
Trends.
Recenzii
From
the
reviews:
"This book examines the international pharmaceutical industry with special emphasis on the current and emerging research methodologies … . What distinguishes this book from others on the same subject is its emphasis on empirical findings (53 figures, 20 tables) and an exceptionally good, if short, discussion of various research technologies … . The six-page glossary of industry terms, when used with its decent index, is a particular joy. … recommend this offering to prospective managers and researchers in this industry … ." (Robert R. Rothberg, Journal of Product Innovation Management, Vol. 22, 2005)
From the reviews of the second edition:
“Leading Pharmaceutical Innovation, Gassmann and colleagues describe the current status of the pharmaceutical industry … . This book comprises seven chapters, where each could be seen as a review of the addressed topic. This helps with understanding the complexity of the challenges the pharmaceutical industry is facing, in comparison to the automotive industry or with respect to marketing problems … . book provides most valuable insight into the pharmaceutical industry from an ‘outsiders’ perspective.” (Sandrine Shepard and Thomas Wilckens, R&D Management, Vol. 40 (5), November, 2010)
"This book examines the international pharmaceutical industry with special emphasis on the current and emerging research methodologies … . What distinguishes this book from others on the same subject is its emphasis on empirical findings (53 figures, 20 tables) and an exceptionally good, if short, discussion of various research technologies … . The six-page glossary of industry terms, when used with its decent index, is a particular joy. … recommend this offering to prospective managers and researchers in this industry … ." (Robert R. Rothberg, Journal of Product Innovation Management, Vol. 22, 2005)
From the reviews of the second edition:
“Leading Pharmaceutical Innovation, Gassmann and colleagues describe the current status of the pharmaceutical industry … . This book comprises seven chapters, where each could be seen as a review of the addressed topic. This helps with understanding the complexity of the challenges the pharmaceutical industry is facing, in comparison to the automotive industry or with respect to marketing problems … . book provides most valuable insight into the pharmaceutical industry from an ‘outsiders’ perspective.” (Sandrine Shepard and Thomas Wilckens, R&D Management, Vol. 40 (5), November, 2010)
Textul de pe ultima copertă
Pharmaceutical
giants
have
doubled
their
investments
in
drug
development
in
the
past
decade
only
to
see
new
drug
approvals
remain
constant.
This
book
investigates
and
highlights
a
set
of
proactive
strategies
aimed
at
generating
sustainable
competitive
advantage
based
on
value-generating
business
practices.
We
focus
on
three
sources
of
pharmaceutical
innovation:
new
management
methods
in
the
drug
development
pipeline,
new
technologies
as
enablers
for
cutting-edge
R&D,
and
new
forms
of
cooperation
and
internationalization,
such
as
open
innovation
in
the
early
phases
of
R&D.
Our
findings
are
illustrated
by
cases
from
Europe,
the
US,
and
Asia.
"One way we try to foster innovation - both the technological innovation and the organizational innovation - is to align our business objectives with our ideals."
Dr. Daniel Vasella, CEO, Novartis International
"Pharmaceutical innovation is in crisis. The industry will have to change both its innovation processes and its business models in order to reverse these trends and prosper in the future. Professors Gassmann, Reepmeyer and von Zedtwitz have marshalled together an impressive array of research in one volume. This book should prove to be an indispensable resource for all participants in the pharmaceutical industry."
Prof. Henry Chesbrough, Executive Director, Center for Open Innovation, Haas School of Business, University of California, Berkeley
"It´s time for a paradigm shift in pharmaceutical R&D. This book will tell you why."
Dr. Goetz Baumann, Business Unit Manager, Hoffmann-La Roche (Germany)
"This book offers a fact based, comprehensive insight to the increasing challenges of today`s drug development. Well worth reading not just for newcomers to the industry but also for industry professionals who want to understand the big picture".
Dr. Pius Renner, Head of Strategic Planning and Portfolio Management in Development, Novartis Pharma
"One way we try to foster innovation - both the technological innovation and the organizational innovation - is to align our business objectives with our ideals."
Dr. Daniel Vasella, CEO, Novartis International
"Pharmaceutical innovation is in crisis. The industry will have to change both its innovation processes and its business models in order to reverse these trends and prosper in the future. Professors Gassmann, Reepmeyer and von Zedtwitz have marshalled together an impressive array of research in one volume. This book should prove to be an indispensable resource for all participants in the pharmaceutical industry."
Prof. Henry Chesbrough, Executive Director, Center for Open Innovation, Haas School of Business, University of California, Berkeley
"It´s time for a paradigm shift in pharmaceutical R&D. This book will tell you why."
Dr. Goetz Baumann, Business Unit Manager, Hoffmann-La Roche (Germany)
"This book offers a fact based, comprehensive insight to the increasing challenges of today`s drug development. Well worth reading not just for newcomers to the industry but also for industry professionals who want to understand the big picture".
Dr. Pius Renner, Head of Strategic Planning and Portfolio Management in Development, Novartis Pharma
Caracteristici
The
book
is
based
on
the
three
most
important
challenges
in
pharmaceutical
innovation:
productivity
dilemma,
new
technology
trends,
globalization
and
outsourcing
Due to the CTO-roundtable with 14 selected international experts in pharmaceutical R&D whose result is presented, the book has a strong perspective from senior management
With management concepts and tools enabling leaders in the pharmaceutical industry to cope with new challenges and trends
Due to the CTO-roundtable with 14 selected international experts in pharmaceutical R&D whose result is presented, the book has a strong perspective from senior management
With management concepts and tools enabling leaders in the pharmaceutical industry to cope with new challenges and trends